Relationship between levels of advanced glycation end products and their soluble receptor and adverse outcomes in adults with type 2 diabetes

Diabetes Care

Volumn 38, Issue 10, 2015, Pages 1891-1897

  Thomas, Merlin C ^a   Woodward, Mark ^b,c,d   Neal, Bruce ^b   Li, Qiang ^b   Pickering, Raelene ^a   Marre, Michel ^e   Williams, Bryan ^f   Perkovic, Vlado ^b   Cooper, Mark E ^a   Zoungas, Sophia ^b,g   Chalmers, John ^b   Hillis, Graham S ^b,h  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e BICHAT HOSPITAL   (France)

^f UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^g MONASH UNIVERSITY   (Australia)

^h ROYAL PERTH HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; HIGH MOBILITY GROUP PROTEIN; INDAPAMIDE PLUS PERINDOPRIL; ADVANCED GLYCATION END PRODUCT RECEPTOR; ANTIDIABETIC AGENT; BIOLOGICAL MARKER; IMMUNOGLOBULIN RECEPTOR;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; FEMALE; GLYCEMIC CONTROL; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; PREVALENCE; PROTEIN PROCESSING; RISK FACTOR; AGED; CLINICAL TRIAL; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; EPIDEMIOLOGY; METABOLISM; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADVANCED GLYCOSYLATION END PRODUCT-SPECIFIC RECEPTOR; AGED; BIOMARKERS; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; EPIDEMIOLOGIC METHODS; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; RECEPTORS, IMMUNOLOGIC; TREATMENT OUTCOME;

EID: 84962439630     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc15-0925     Document Type: Article

References (37)

1. Chalmers J, Cooper ME. UKPDS and the legacy effect. N Engl J Med 2008;359:1618-1620.
2. Thomas MC. Glycemic exposure, glycemic control, and metabolic karma in diabetic complications. Adv Chronic Kidney Dis 2014;21: 311-317.
3. Bierhaus A, Fleming T, Stoyanov S, et al. Methylglyoxal modification of Nav1.8 facilitates nociceptive neuron firing and causes hyperalgesia in diabetic neuropathy. Nat Med 2012;18: 926-933.
4. Goldin A, Beckman JA, Schmidt AM, Creager MA. Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation 2006;114:597-605.
5. Calcutt NA, Cooper ME, Kern TS, Schmidt AM. Therapies for hyperglycaemia-induced diabetic complications: from animal models to clinical trials. Nat Rev Drug Discov 2009;8:417-429.
6. Singh R, Barden A, Mori T, Beilin L. Advanced glycation end-products: A review. Diabetologia 2001;44:129-146.
7. Thomas MC, Tikellis C, Burns WM, et al. Interactions between renin angiotensin system and advanced glycation in the kidney. J Am Soc Nephrol 2005;16:2976-2984.
8. Harja E, Bu DX, Hudson BI, et al. Vascular and inflammatory stresses mediate atherosclerosis via RAGE and its ligands in apoE-/- mice. J Clin Invest 2008;118:183-194.
9. Zhang L, Bukulin M, Kojro E, et al. Receptor for advanced glycation end products is subjected to protein ectodomain shedding by metalloproteinases. J Biol Chem 2008;283: 35507-35516.
10. Challier M, Jacqueminet S, Benabdesselam O, Grimaldi A, Beaudeux JL. Increased serum concentrations of soluble receptor for advanced glycation endproducts in patients with type 1 diabetes. Clin Chem 2005;51:1749-1750.
11. Nakamura K, Yamagishi S, Adachi H, et al. Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are positively associated with circulating AGEs and soluble form of VCAM-1 in patients with type 2 diabetes. Microvasc Res 2008;76:52-56.
12. Yamagishi S, Matsui T. Soluble form of a receptor for advanced glycation end products (sRAGE) as a biomarker. Front Biosci (Elite Ed) 2010;2:1184-1195.
13. Thomas MC, Söderlund J, Lehto M, et al.; FinnDiane Study Group. Soluble receptor for AGE (RAGE) is a novel independent predictor of all-cause and cardiovascular mortality in type 1 diabetes. Diabetologia 2011;54:2669-2677.
14. Nin JW, Jorsal A, Ferreira I, et al. Higher plasma soluble receptor for advanced glycation end products (sRAGE) levels are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: A 12-year follow-up study. Diabetes 2010;59:2027-2032.
15. Colhoun HM, Betteridge DJ, Durrington P, et al. Total soluble and endogenous secretory receptor for advanced glycation end products as predictive biomarkers of coronary heart disease risk in patients with type 2 diabetes: An analysis from the CARDS trial. Diabetes 2011;60:2379- 2385.
16. Patel A, MacMahon S, Chalmers J, et al.; ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-2572.
17. Patel A, MacMahon S, Chalmers J, et al.; ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): A randomised controlled trial. Lancet 2007;370:829-840.
18. ADVANCE Management Committee. Study rationale and design of ADVANCE: Action in Diabetes and Vascular Disease-Preterax and Diamicron MR controlled evaluation. Diabetologia 2001;44:1118-1120.
19. Levey AS, Stevens LA, Schmid CH, et al.; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150:604-612.
20. Hillis GS, Welsh P, Chalmers J, et al. The relative and combined ability of high-sensitivity cardiac troponin T and N-terminal pro-B-type natriuretic peptide to predict cardiovascular events and death in patients with type 2 diabetes. Diabetes Care 2014;37:295-303.
21. Welsh P, Woodward M, Hillis GS, et al. Do cardiac biomarkers NT-proBNP and hsTnT predict microvascular events in patients with type 2 diabetes? Results from the ADVANCE trial. Diabetes Care 2014;37:2202-2210.
22. Lowe G, Woodward M, Hillis G, et al. Circulating inflammatory markers and the risk of vascular complications and mortality in people with type 2 diabetes and cardiovascular disease or risk factors: The ADVANCE study. Diabetes 2014;63:1115-1123.
23. Chambless LE, Cummiskey CP, Cui G. Several methods to assess improvement in risk prediction models: Extension to survival analysis. Stat Med 2011;30:22-38.
24. Pencina MJ, D'Agostino RB Sr, Steyerberg EW. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med 2011;30:11-21.
25. Bucciarelli LG, Wendt T, Qu W, et al. RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation 2002;106:2827-2835.
26. Selvin E, Halushka MK, Rawlings AM, et al. sRAGE and risk of diabetes, cardiovascular disease, and death. Diabetes 2013;62:2116-2121.
27. Falcone C, Emanuele E, D'Angelo A, et al. Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. Arterioscler Thromb Vasc Biol 2005;25:1032-1037.
28. Lindsey JB, de Lemos JA, Cipollone F, et al. Association between circulating soluble receptor for advanced glycation end products and atherosclerosis: observations from the Dallas Heart Study. Diabetes Care 2009;32:1218-1220.
29. Rebholz CM, Astor BC, Grams ME, et al. Association of plasma levels of soluble receptor for advanced glycation end products and risk of kidney disease: The Atherosclerosis Risk in Communities study. Nephrol Dial Transplant 2015; 30:77-83.
30. Soro-Paavonen A, Watson AM, Li J, et al. Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes. Diabetes 2008; 57:2461-2469.
31. Forbes JM, Cooper ME. Mechanisms of diabetic complications. Physiol Rev 2013;93:137- 188.
32. Kanková K, Kalousová M, Hertlová M, Krusová D, Olsovský J, Zima T. Soluble RAGE, diabetic nephropathy and genetic variability in the AGER gene. Arch Physiol Biochem 2008;114: 111-119.
33. Gohda T, Tanimoto M, Moon JY, et al. Increased serum endogenous secretory receptor for advanced glycation end-product (esRAGE) levels in type 2 diabetic patients with decreased renal function. Diabetes Res Clin Pract 2008;81: 196-201.
34. Grossin N, Wautier MP, Meas T, Guillausseau PJ, Massin P, Wautier JL. Severity of diabetic microvascular complications is associated with a low soluble RAGE level. Diabetes Metab 2008;34: 392-395.
35. Nakamura K, Yamagishi S, Adachi H, et al. Serum levels of sRAGE, the soluble form of receptor for advanced glycation end products, are associated with inflammatory markers in patients with type 2 diabetes. Mol Med 2007;13: 185-189.
36. Fujisawa K, Katakami N, Kaneto H, et al. Circulating soluble RAGE as a predictive biomarker of cardiovascular event risk in patients with type 2 diabetes. Atherosclerosis 2013;227:425-428.
37. Lutgers HL, Graaff R, Links TP, et al. Skin autofluorescence as a noninvasive marker of vascular damage in patients with type 2 diabetes. Diabetes Care 2006;29:2654-2659.